Travere (TVTX) Q1 2026 Earnings Transcript

Travere reported $127.2 million in Q1 revenue, with Filspari U.S. net product sales rising 88% year over year to $105.2 million and 993 new patient start forms, the highest quarterly demand since launch. The company also secured the first full FDA approval for Filspari in FSGS, expanding the addressable U.S. patient pool to more than 100,000 across IgA nephropathy and FSGS and reiterating $3 billion in peak sales potential. Management said FSGS access is already above 97% and restarted HARMONY enrollment in pegtobatinase, with topline data expected in 2027.

Analysis

TVTX is transitioning from a single-asset launch story to a two-indication commercial platform, and that changes the multiple more than the quarter itself. The key second-order effect is that FSGS should be a lower-friction payer and prescriber education event than the original IgAN rollout because the same nephrology channel, same diagnostic workflow, and same reimbursement infrastructure are now being reused; that creates operating leverage in both sales efficiency and gross-to-net dilution over the next 2-3 quarters. The market is likely underappreciating how quickly the company can turn a broader approved label into a denser prescribing base once community nephrologists realize this is a label-expansion, not a cold-start launch.

The contrarian issue is that the “faster than IgAN” narrative can become self-defeating if investors extrapolate early PSF momentum too aggressively. In the near term, the launch mix is likely to be noisy because some early FSGS volume will come from existing prescribers, while true incremental penetration will depend on how quickly the company resolves label education around active nephrotic syndrome and demonstrates durable payer conversion in the next 60-90 days. If access friction shows up, the implied $3B peak becomes more of a 2029+ story than a 2027 story.

The pipeline is the cleaner longer-dated optionality. Pegtobatinase has enough mechanistic signal to matter, but HCU is a binary, multi-year catalyst and should be valued as call option rather than core enterprise value until HARMONY de-risks in 2027. Net-net, the stock should trade on whether the market believes TVTX can compound at a mid-30%+ top-line clip without a capital raise; the balance sheet and emerging non-GAAP profitability make that plausible, but not yet proven.

Key Decisions for Investors

• Long TVTX common for a 3-6 month catalyst window; use any pullback on launch skepticism to build, targeting a rerate if FSGS access and early demand sustain through the next two quarters.
• Buy TVTX Jan-2027 or Jan-2028 calls to express the $3B peak-sales optionality with limited downside; risk/reward improves if the market keeps discounting FSGS contribution as 'too early.'
• Pair trade: long TVTX / short NVS on IgAN share growth and label momentum; if the competitive set remains fragmented, TVTX should capture the highest share of market expansion while NVS bears the burden of proving share gains.
• If liquidity-sensitive, hedge TVTX long exposure with a partial short in biotech basket ETF or a broad healthcare short, since the main risk is multiple compression if early FSGS adoption decelerates before the June/July data points.
• Avoid chasing after large gap-ups; add only on days when the market focuses on PSF optics rather than durable payer conversion, because the real re-rating trigger is 2Q evidence, not day-one launch commentary.